Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Non-Hodgkin's lymphomas (NHLs) encompass diverse lymphoproliferative disorders arising from B, T, or NK lymphocytes, accounting for 4-5% of new cancer diagnoses.
• Classification relies on the WHO system, integrating cell lineage, morphology, immunophenotype, and genetics, with molecular profiling enhancing diagnostic accuracy and prognostic marker identification.

Purpose of the Study:

• To review the classification, pathogenesis, and evolving treatment strategies for Non-Hodgkin's lymphomas.
• To highlight the significance of molecular alterations in understanding NHL subtypes and guiding therapeutic decisions.

Main Methods:

• Literature review of recent studies on NHL classification, molecular mechanisms, and treatment advancements.
• Analysis of diagnostic approaches, including integrated methods for leukemic presentations and the role of biopsy material.

Main Results:

• Indolent NHLs (e.g., follicular lymphoma, marginal zone lymphoma) generally have a favorable prognosis.
• Aggressive diffuse large B-cell lymphoma (DLBCL) is the most common subtype, with specific genetic alterations like MYC translocations and 'double hit' lymphomas (MYC and BCL2/BCL6) indicating a poor prognosis.
• Chemoimmunotherapy is standard for indolent NHLs, while intensified regimens and targeted agents are emerging for aggressive or refractory disease.

Conclusions:

• Continued research into the genetic and microenvironmental factors driving lymphomagenesis is essential for personalized therapeutic strategies in NHL.
• Advances in molecular profiling are crucial for refining NHL classification, identifying prognostic markers, and developing novel targeted treatments.